Professor Anthony Harnden has congratulated the trio of Agency board members on the extension of their appointments.
Similar Posts
Notice: Medicines: terminated and cancelled manufacturing and wholesale dealer licences
UK companies who have their licence to manufacture or wholesale medicines terminated and cancelled.
Clinical trials for medicines: expert advice
Clinical trial applications that need expert advice from a specialist group or committee.
Decision: Advertising Investigations: July 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
Medicines: Marketing Authorisation Holders’ submission of Nitrosamine risk evaluation, risk assessment and confirmatory testing
Marketing Authorisation Holders should review their manufacturing processes to identify and, if found, to mitigate the risk of nitrosamine impurities being present.
Cosmetic Breast Augmentation Risk Awareness Tool
New Cosmetic Breast Augmentation Risk Awareness Tool for patients to use when considering cosmetic breast implant surgery.
Decision: Advertising Investigations: June 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.